> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Used on Migraine Drug Approval
- URL: https://www.fdaweb.com/priority-review-used-on-migraine-drug-approval/
- Published: 2020-05-29T12:00:00.000Z
- Updated: 2026-09-14T16:16:32.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146887

*Federal Register* notice: FDA is providing notification that it approved a drug product that relied on a priority review voucher for approval — Biohaven Pharmaceutical Holding’s NDA for Nurtec ODT (rimegepant) for the acute treatment of migraine in adults. The drug was approved in February based on data from a Phase 3 clinical trial (Study 303) and a long-term, open-label safety study (Study 201). To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-11681.pdf?ref=fdaweb.com).